谁需要抗血小板治疗？
Who needs antiplatelet therapy?
作者信息
Moher M, Lancaster T
机构信息
ICRF General Practice Research Group, University Department of Public Health and Primary Care, Oxford.
出版信息
Br J Gen Pract. 1996 Jun;46(407):367-70.
Abstract
A series of overviews or meta-analyses of randomized clinical trials prepared by the Antiplatelet Trialists' Collaboration were published in the British Medical Journal in January 1994. They demonstrated that prolonged courses of medium-dose aspirin were very effective at preventing both fatal and non-fatal myocardial infarction and stroke in patients at high risk of occlusive vascular disease. The aim of this review is to provide the general practitioner with a practical guide to the use of aspirin in patients at high and low risk of occlusive vascular disease and to discuss appropriate dosages and contraindications to treatment in the light of all the recent evidence.
摘要
抗血小板治疗协作组编制的一系列关于随机临床试验的综述或荟萃分析于1994年1月发表在《英国医学杂志》上。这些研究表明，对于患有闭塞性血管疾病高风险的患者，较长疗程的中等剂量阿司匹林在预防致命性和非致命性心肌梗死及中风方面非常有效。本综述的目的是为全科医生提供一份关于在闭塞性血管疾病高风险和低风险患者中使用阿司匹林的实用指南，并根据所有最新证据讨论适当的剂量和治疗禁忌症。
相似文献
1
Who needs antiplatelet therapy?谁需要抗血小板治疗？
Br J Gen Pract. 1996 Jun;46(407):367-70.
2
Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.抗血小板治疗随机试验的协作综述——I：各类患者长期抗血小板治疗预防死亡、心肌梗死和中风。抗血小板试验协作组。
BMJ. 1994 Jan 8;308(6921):81-106.
3
Update on aspirin in the treatment and prevention of cardiovascular disease.阿司匹林在心血管疾病治疗与预防中的最新进展。
Am J Manag Care. 2002 Dec;8(22 Suppl):S691-700.
4
Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.普伐他汀和阿司匹林降低心血管疾病风险的附加益处：二级预防试验的随机和观察性比较及其荟萃分析
Arch Intern Med. 2004 Jan 12;164(1):40-4. doi: 10.1001/archinte.164.1.40.
5
Aspirin in the secondary prevention of cardiovascular disease: an update of the APTC meta-analysis.阿司匹林在心血管疾病二级预防中的应用：APTC 荟萃分析的更新。
Fundam Clin Pharmacol. 2010 Jun;24(3):385-91. doi: 10.1111/j.1472-8206.2009.00769.x. Epub 2009 Aug 12.
6
The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.在心血管疾病的治疗和预防中更广泛且适当地使用阿司匹林和他汀类药物的必要性。
Expert Rev Cardiovasc Ther. 2008 Jan;6(1):95-107. doi: 10.1586/14779072.6.1.95.
7
Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists' Collaboration.通过长期抗血小板治疗进行血管疾病的二级预防。抗血小板治疗协作组。
Br Med J (Clin Res Ed). 1988 Jan 30;296(6618):320-31.
8
Antiplatelet therapy in the treatment of atherothrombotic disease: considering the evidence.抗血小板治疗在动脉粥样硬化血栓形成性疾病治疗中的应用：审视相关证据
Geriatrics. 2007 Apr;62(4):12-24.
9
Aspirin: promise and resistance in the new millennium.阿司匹林：新千年中的前景与阻力
Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):s25-32. doi: 10.1161/ATVBAHA.107.160481. Epub 2008 Jan 3.
10
Antithrombotic drugs for the secondary prevention of ischemic stroke.用于缺血性中风二级预防的抗血栓药物。
Ann Ital Med Int. 2000 Oct-Dec;15(4):282-90.
引用本文的文献
1
Hematoma Expansion Following Intracerebral Hemorrhage: Mechanisms Targeting the Coagulation Cascade and Platelet Activation.脑出血后血肿扩大：靶向凝血级联和血小板激活的机制。
Curr Drug Targets. 2017;18(12):1329-1344. doi: 10.2174/1389450118666170329152305.
2
North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England Aspirin Guideline Development Group.英格兰北部循证指南制定项目：初级保健中阿司匹林用于血管疾病二级预防的指南。英格兰北部阿司匹林指南制定小组。
BMJ. 1998 Apr 25;316(7140):1303-9. doi: 10.1136/bmj.316.7140.1303.
3
Antiplatelet therapy.抗血小板治疗。
Br J Gen Pract. 1996 Aug;46(409):494-5.
本文引用的文献
1
The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials.阿司匹林的胃肠道毒性：随机对照试验综述
Br J Clin Pharmacol. 1993 Mar;35(3):219-26. doi: 10.1111/j.1365-2125.1993.tb05689.x.
2
Use of warfarin in non-rheumatic atrial fibrillation: a commentary from general practice.华法林在非风湿性心房颤动中的应用：来自全科医疗的评论
Br J Gen Pract. 1995 Mar;45(392):153-8.
3
Conveying the benefits and risks of treatment.传达治疗的益处和风险。
Br J Gen Pract. 1995 Jul;45(396):339-41.
4
Aspirin and acute myocardial infarction: clarifying the message.阿司匹林与急性心肌梗死：厘清相关信息。
Br J Gen Pract. 1995 Aug;45(397):395-6.
5
Natural history of angina pectoris in the Framingham study. Prognosis and survival.弗明汉姆研究中心关于心绞痛的自然病史。预后与生存情况。
Am J Cardiol. 1972 Feb;29(2):154-63. doi: 10.1016/0002-9149(72)90624-8.
6
Risk factors for ischaemic heart disease: the prospective phase of the British Regional Heart Study.缺血性心脏病的风险因素：英国地区心脏研究的前瞻性阶段
J Epidemiol Community Health. 1985 Sep;39(3):197-209. doi: 10.1136/jech.39.3.197.
7
Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study.心房颤动：老年人中风的主要诱因。弗雷明汉姆研究。
Arch Intern Med. 1987 Sep;147(9):1561-4.
8
An assessment of clinically useful measures of the consequences of treatment.对治疗后果的临床有用测量方法的评估。
N Engl J Med. 1988 Jun 30;318(26):1728-33. doi: 10.1056/NEJM198806303182605.
9
Rapid resolution of signs of primary intracerebral haemorrhage in computed tomograms of the brain.脑部计算机断层扫描中原发性脑出血征象的快速消退。
Br Med J (Clin Res Ed). 1987 Aug 8;295(6594):379-81. doi: 10.1136/bmj.295.6594.379.
10
Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.华法林与阿司匹林预防慢性心房颤动血栓栓塞并发症的安慰剂对照随机试验。哥本哈根AFASAK研究。
Lancet. 1989 Jan 28;1(8631):175-9. doi: 10.1016/s0140-6736(89)91200-2.
Zotero 插件